	US 12,263,164 B2
	Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Ahmed Hamdy, Santa Cruz, CA (US); Wayne Rothbaum, New York, NY (US); Raquel Izumi, San Carlos, CA (US); Brian Lannutti, Solana Beach, CA (US); Todd Covey, San Carlos, CA (US); Roger Ulrich, Sammamish, WA (US); Dave Johnson, Aptos, CA (US); Tjeerd Barf, Ravenstein (NL); and Allard Kaptein, Zaltbommel (NL)
Assigned to Acerta Pharma B.V., Oss (NL)
Filed by Acerta Pharma B.V., Oss (NL)
Filed on Aug. 16, 2023, as Appl. No. 18/451,030.
Application 18/451,030 is a continuation of application No. 17/370,778, filed on Jul. 8, 2021, granted, now 11,771,696.
Application 17/370,778 is a continuation of application No. 16/298,094, filed on Mar. 11, 2019, granted, now 11,090,302, issued on Aug. 17, 2021.
Application 16/298,094 is a continuation of application No. 15/112,968, granted, now 10,272,083, issued on Apr. 30, 2019, previously published as PCT/IB2015/000645, filed on Jan. 21, 2015.
Claims priority of provisional application 62/035,777, filed on Aug. 11, 2014.
Claims priority of provisional application 61/974,665, filed on Apr. 3, 2014.
Claims priority of provisional application 61/929,742, filed on Jan. 21, 2014.
Prior Publication US 2024/0180904 A1, Jun. 6, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4985 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01)

CPC A61K 31/4985 (2013.01) [A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07K 16/2887 (2013.01); C07K 2317/24 (2013.01); C07K 2317/732 (2013.01)]

18 Claims

1. A method of treating Waldenström's macroglobulinemia (WM) in a human subject suffering therefrom, comprising the step of orally administering to the human subject, a dose of 100 mg twice daily of a Bruton's tyrosine kinase (BTK) inhibitor, wherein the BTK inhibitor is a compound of Formula II:

or a pharmaceutically-acceptable salt, hydrate, or solvate thereof.